DK1632248T3 - Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed - Google Patents

Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed

Info

Publication number
DK1632248T3
DK1632248T3 DK05009688.2T DK05009688T DK1632248T3 DK 1632248 T3 DK1632248 T3 DK 1632248T3 DK 05009688 T DK05009688 T DK 05009688T DK 1632248 T3 DK1632248 T3 DK 1632248T3
Authority
DK
Denmark
Prior art keywords
interleukin
antibody
treatment
receptor
bronchial hypersensitivity
Prior art date
Application number
DK05009688.2T
Other languages
English (en)
Inventor
W Lee Maloy
Prasad U Kari
Nicholas Nicolaides
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Application granted granted Critical
Publication of DK1632248T3 publication Critical patent/DK1632248T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK05009688.2T 1995-08-24 1996-08-23 Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed DK1632248T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2380096P 1996-08-06 1996-08-06
EP96929657A EP0846173B1 (en) 1995-08-24 1996-08-23 Use of an anti-interleukin-9 antibody for the preparation of a medicament for the treatment of asthma

Publications (1)

Publication Number Publication Date
DK1632248T3 true DK1632248T3 (da) 2011-01-24

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05009688.2T DK1632248T3 (da) 1995-08-24 1996-08-23 Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed
DK96929657T DK0846173T3 (da) 1995-08-24 1996-08-23 Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96929657T DK0846173T3 (da) 1995-08-24 1996-08-23 Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma

Country Status (10)

Country Link
EP (3) EP0846173B1 (da)
JP (3) JP3948495B2 (da)
AT (2) ATE484294T1 (da)
AU (1) AU6895696A (da)
CA (2) CA2230240C (da)
DE (2) DE69638281D1 (da)
DK (2) DK1632248T3 (da)
ES (2) ES2249786T3 (da)
PT (1) PT1632248E (da)
WO (1) WO1997008321A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
EP1471144B1 (en) * 1996-12-02 2010-06-23 Genaera Corporation Biological variability of asthma associated factor AAF2 (IL-9 receptor) useful in treating and diagnosing atopic allergies including asthma and related disorders
JP4552076B2 (ja) * 1996-12-02 2010-09-29 ジェネーラ コーポレーション 喘息および関連疾患を含むアトピー性アレルギーの治療および診断に有用なｉｌ−９受容体変異体
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
JP2001517682A (ja) * 1997-09-19 2001-10-09 マガイニン ファーマシューティカルズ インク． 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
CA2302782A1 (en) * 1997-09-19 1999-03-25 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
CA2370821A1 (en) * 1999-05-01 2000-11-09 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US20040219149A1 (en) 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
ATE470858T1 (de) * 2001-02-22 2010-06-15 Univ New York State Res Found Opiatrezeptoren
CA2522007A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
WO1995027052A1 (en) 1994-03-30 1995-10-12 University Of Maryland At Baltimore Human interleukin variants generated by alternative splicing

Also Published As

Publication number Publication date
EP1632248B8 (en) 2010-12-29
CA2666298A1 (en) 1997-03-06
JP3948495B2 (ja) 2007-07-25
JP2011152135A (ja) 2011-08-11
DE69638281D1 (de) 2010-11-25
JP2007169287A (ja) 2007-07-05
PT1632248E (pt) 2010-12-28
CA2230240C (en) 2009-08-18
DE69635305D1 (de) 2006-03-02
EP2241329A2 (en) 2010-10-20
EP1632248A1 (en) 2006-03-08
ES2249786T3 (es) 2006-04-01
EP2241329A3 (en) 2011-03-09
JPH11514851A (ja) 1999-12-21
CA2230240A1 (en) 1997-03-06
WO1997008321A1 (en) 1997-03-06
DK0846173T3 (da) 2006-01-16
DE69635305T2 (de) 2006-07-06
EP0846173B1 (en) 2005-10-19
EP0846173A1 (en) 1998-06-10
ATE484294T1 (de) 2010-10-15
ATE307203T1 (de) 2005-11-15
JP4813380B2 (ja) 2011-11-09
AU6895696A (en) 1997-03-19
EP1632248B1 (en) 2010-10-13
ES2354360T3 (es) 2011-03-14

Similar Documents

Publication Publication Date Title
DK1632248T3 (da) Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed
DK1382348T3 (da) Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
DK0951282T3 (da) Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
ATE133564T1 (de) Flupirtin in kombination mit antiparkinsonika zur bekämpfung von muskelverspannungen
DK0751129T3 (da) Substituerede dihydrodibenz/b,f/azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle li
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
FR2684289B1 (fr) Implant intra-cortical, notamment pour la fixation de ligament.
FR2684543B1 (fr) Ligament artificiel, notamment pour la cheville.
NO992674D0 (no) Konturen til et transdermalt terapeutisk system
DK671087A (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
BR0208554A (pt) Osteoprotegerina no leite
DK0601152T3 (da) Osteosyntesehjælpemiddel til fiksering af knogler.
DE69734461D1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
DE29501724U1 (de) Spachtel zur Nachbearbeitung von Silikonfugen o.dgl.
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
DK0956038T3 (da) Morfogen peptidinduceret regeneration af senseopfattelsesvæv
ES1004869Y (es) Atadura para la fijacion de sarmientos.
ES2022325B3 (es) Composicion formadora de fibra absorbente de agua, objeto que la contiene y metodo para obtener dicha composicion y dicho objeto.
DK475989A (da) Anvendelse af pyrazolopyridinderivater eller fysiologisk acceptable salte deraf i laegmidler til behandling af epilepsi
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
ES1013923Y (es) Atadura para la fijacion de sarmientos.
DE69002821D1 (de) Zusammensetzung zur haarbehandlung.
BR9709007A (pt) Uso de azaspirano substituìdo no tratamento da asma.